Korean J Obstet Gynecol.
2006 Dec;49(12):2459-2472.
Comparison of Anti-osteoporotic Medications and Alternatives
- Affiliations
-
- 1Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea. bmkang@amc.seoul.kr
Abstract
- Osteoporosis becomes a serious health threat for aging postmenopausal women by predisposing them to an increased risk of fracture. Conventional pharmacological options are available for osteoporosis therapy, including bisphosphonates, the SERM raloxifene, estrogens, clacitonin, and parathyroid hormone. Although alternative treatment regimens, such as phytoestrogens, herbals, and dehydroepiandrosterone (DHEA) also show beneficial effect on bone density and health, further study to determine optional formulation is needed. Several new drugs are available or are in clinical development.
MeSH Terms
-
Aging
Bone Density
Dehydroepiandrosterone
Diphosphonates
Estrogens
Female
Humans
Osteoporosis
Parathyroid Hormone
Phytoestrogens
Raloxifene
Selective Estrogen Receptor Modulators
Raloxifene Hydrochloride
Dehydroepiandrosterone
Diphosphonates
Estrogens
Parathyroid Hormone
Phytoestrogens
Selective Estrogen Receptor Modulators
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Customized Treatment for the Prevention of Osteoporotic Fracture
- The National Use of Antiosteoporosis Medication in 2009
- Management of Osteoporosis Medication after Osteoporotic Fracture
- The combined use of anti-peptic agents is associated with an increased risk of osteoporotic fracture: a nationwide case-control study
- Management of Osteoporotic Vertebral Fracture: Review Update 2022
